Nutrition and depression: A review of the evidence

Journal of Mental Health

Volumn 17, Issue 6, 2008, Pages 576-587

  Harbottle, Lynn ^a   Schonfelder, Nicola ^b  

^a Princess Elizabeth Hospital   (United Kingdom)

^b BASILDON HOSPITAL   (United Kingdom)

Author keywords

Carbohydrate; Depression; Folate; Omega 3; Supplementation; Tryptophan; Zinc; ZincB12

Indexed keywords

5 HYDROXYTRYPTOPHAN; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FLUOXETINE; FOLIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; TRAZODONE; TRYPTOPHAN; ZINC;

ADJUVANT THERAPY; BELCHING; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EXCITEMENT; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION RETRIEVAL; INSOMNIA; LOOSE FECES; MAJOR DEPRESSION; META ANALYSIS; MONOAMINE METABOLISM; MONOTHERAPY; NUTRITION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TASTE AVERSION; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

EID: 56249089724     PISSN: 09638237     EISSN: 13600567     Source Type: Journal    
DOI: 10.1080/09638230701677746     Document Type: Review

References (46)

1. Adams, P. B., Lawson, S., Sanigorski, A., & Sinclair, A. J. (1996). Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids, 31 (Suppl.), S157-S161.
2. Alino, J. J., Gutierrez, J. L., & Iglesias, M. L. (1976). 5-hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. International Pharmacopsychiatry, 11, 8-15.
3. Bottiglieri, T., Laundy, M., Crellin, R., Toone, B. K., Carney, M. W. P., & Reynolds, E. H. (2000). Homocysteine, folate, methylation, and monoamine metabolism in depression. Journal of Neurological Neurosurgery and Psychiatry, 69, 228-232.
4. Bourre, J. M. (2004). Roles of unsaturated fatty acids (especially omega 3 fatty acids) in the brain at various ages and during ageing. Journal of Nutrition in Health and Ageing, 8, 163-174.
5. Coppen, A., & Bailey, J. (2000). Enhancement of antidepressant action of fluoxetine by folic acid: A randomised controlled trial. Journal of Affective Disorders, 60, 121-130.
6. Department of Health (1991). Report of the Panel on Dietary Reference Values of the Committee on Medical Aspects of Food Policy (COMA). Dietary Reference Values for Food Energy and Nutrients for the United Kingdom. Report on Health and Social Subjects 41. London: HMSO.
7. Edwards, R., Peet, M., Shay, J., & Horrobin, D. (1998). Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. Journal of Affective Disorders, 48, 149-155.
8. Fava, M., Borus, J. S., & Alpert, J. E. (1997). Folate, B12 and homocysteine in major depressive disorder. American Journal of Psychiatry, 154, 426-428.
9. Godfrey, P. S., Toone, B. K., Carney, M. W., Flynn, T. G., Bottiglieri, T., Laudy, M., Chanarin, I., & Reynold, E. H. (1990). Enhancement of recovery from psychiatric illness by methylfolate. Lancet, 336, 392-395.
10. Harbige, L. S. (2003). Fatty acids, the immune response and auto-immunity: A question of n-6 essentiality and the balance between n-6 and n-3. Lipids, 3, 323-341.
11. Hibbeln, J. R. (1998). Fish consumption and major depression [letter]. Lancet, 351, 1213.
12. Hintikka, J., Tolmunen, T., Tanskanen, A., & Viinamaki, H. (2003). High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. Biomedical Central Psychiatry, 3, 17.
13. Maes, M., D'Haese, P. C., Scharpe, S., D'Hondt, P. D., Cosyns, P., & De Broe, M. E. (1994). Hypozincaemia in depression. Journal of Affective Disorders, 31, 135-140.
14. Maes, M., Wauters, A., Verkerk, R., Demedts, P., Neels, H., Van Gastel, A., Cosyns, P., Scharpe, S., & Desnyder, R. (1996). Lower serum L-tryptophan availability in depression as a marker of a more generalised disorder in protein metabolism. Neuropsychopharmacology, 15, 243-251.
15. Maes, M., Smith, R., Christophe, A., Cosyns, P., Desnyder, R., & Meltzer, H. (1996). Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. Journal of Affective Disorders, 38, 35-46.
16. Maes, M., Vandoolaeghe, E., Neels, H., Demedts, P., Wauters, A., Meltzer, D., Altamura, C., & Desnyder, R. (1997). Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response to that illness. Biological Psychiatry, 42, 349-358.
17. Mamalakis, G., Kiriakakis, M., Tsibinos, G., & Kafatos, A. (2003). Depression and adipose polyunsaturated fatty acids in the survivors of the seven countries study population of Crete. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70, 495-501.
18. Marangell, L. B., Martinez, J. M., Zboyan, B. A., Seung Kim, H. F., & Puryear, L. J. (2003). A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. American Journal of Psychiatry, 160, 996-998.
19. Marchiolli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., Mantini, L., Marfisi, R. M., Mastroguiseppe, G., Minnini, N., Nicolosi, G. L., Santini, M., Schweiger, C., Tavazzi, L., Tognoni, G., Tucci, C., Valgussa, F., GISSI Preventione Investigators (2002). Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarct Miocardio (GISSI)-Prevenzione. Circulation, 105, 1897-1903.
20. Murray, O., & Lopez, A. D. (1997). Global mortality, disability and the contribution of risk factors. Global burden of disease study. Lancet, 349, 1436-1442.
21. Nardini, M., De Stefano, R., Iannucecelli, M., Borghesi, R., & Battistini, N. (1983). Treatment of depression with L-5-hydroxytryphtophan combined with chlorimipramine, a double-blind study. International Journal Clinical Phamacology Research, 3, 239-250.
22. Nehmets, B., Stahl, Z., & Belmaker, R. H. (2002). Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. American Journal of Psychiatry, 159, 477-479.
23. NICE (2004). Nice guidelines to improve the treatment and care of people with depression and anxiety. www.nice.org.uk/pdf/ 2004_50_launchdepressionanxiety.pdf
24. Nowak, G., & Szewczyk, B. (2002). Mechanisms contributing to antidepressant zinc actions. Polish Journal of Pharmacology, 54, 587-592.
25. Nowak, G., Siwek, M., Dudek, D., Zieba, A., & Pilc, A. (2003). Effect of zinc supplementation on antidepressant therapy in unipolar depression:Apreliminary placebo-controlled study. Polish Journal of Pharmacology, 55, 1143-1147.
26. Passeri, M., Cucionotta, D., Abate, G., Senin, U., Ventura, S., Stramba, B. M., Diana, R., La Greca, P., & Le Grazie, C. (1993). Oral 5-methultetrahydrofolate in senile organic mental disorders with depression: results of a double-blind multicenter study. Ageing, 5, 63-71.
27. Passeri, M., Ventura, S., Abate, G., Cucionotta, D., Senin, U., Stramba, B. M., & Diana, R. (1991). Oral 5-methultetrahydrofolate (MTHF) in depressed associated with senile organic mental disorders (OMDs): a double-blind multicenter study vs. trazone (TRZ). European Journal of Clinical Investigation, 21 (2 Pt II), 24.
28. Peet, M., Murphy, B., Shay, J., & Horrobin, D. (1998). Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biological Psychiatry, 43, 315-319.
29. Peet, M., & Horrobin, D. F. (2002). A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Archives of General Psychiatry, 59, 913-919.
30. Peet, M., & Bennett, C. N. (2003). Relationship between brain lipids, depression and suicide. In M. Peet, I. Glen, D. F. Horrobin (Eds), Phospholipid spectrum disorder in psychiatry and neurology, 2nd edn. (pp. 403-408). Carnforth: Marius Press.
31. Peet, M. (2004). Nutrition and depression. Durham: Northern Centre for Mental Health.
32. Quadbeck, H., Lehmann, E., & Tegeler, J. (1984). Comparison of the antidepressant effect of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine. Neuropsychobiology, 11, 111-114.
33. Richardson, A. J. (2003). The importance of omega-3 fatty acids for behaviour, cognition and mood. Scandinavian Journal of Nutrition, 4, 92-98.
34. Rousseau, J. J. (1987). Effects of levo-5-hydroxytryptophan on depression and neuropsychic performance: a doubleblind placebo-controlled clinical trial in elderly patients. Clinical Therapeutics, 9, 267-272.
35. Sandsead, H., Fredercikson, C. J., & Penland, J. G. (2000). History of zinc related to brain function. Journal of Nutrition, 130, 496S-502S.
36. Shaw, K., Turner, J., & Del Mar, C. (2004). Tryptophan and 5-Hydroxytryptophan for depression (Cochrane Review). In: The Cochrane Library, Issue 3. Chichester: John Wiley and Sons.
37. SIGN (2004). SIGN 50: A Guideline Developer's Handbook. www.sign.ac.uk/guidelines/fulltext/50/section6.html
38. Singleton, N., Bumpstead, R., O'Brien, M., Lee, A., & Meltzer, H. (2000). Psychiatric morbidity among adults living in private households in Great Britain: Summary Report. London: The Office for National Statistics.
39. Smith, K. A., Fairburn, C. G., & Cowen, P. J. (1997). Relapse of depression after rapid depletion of tryptophan. The Lancet, 349, 915-919.
40. Su, K. P., Huang, S. Y., Chiu, C. C., & Shen, W. W. (2003). Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. European Neuropsychopharmacology, 13, 267-271.
41. Tamminga, C. A., Nemeroff, C. B., Blakely, R. D., Brady, L., Carter, C. S., Davis, K. L., Dingledine, R., Gorman, J. M., Grigoriadis, D. E., Henderson, D. C., Innis, R. B., Killen, J., Laughren, T. P., McDonald, W. M., Murphy, G. M., Paul, S. M., Rudorfer, M. V., Sausville, E., Schtzberg, A. F., Scolnick, E. M., & Suppes, T. (2002). Developing novel treatments for mood disorders: Accelerating recovery. Society of Biological Psychiatry, 52, 589-609.
42. Taylor, M. J., Carney, S., Geddes, J., & Goodwin, G. (2004). Folate for depressive disorders (Cochrane Review). The Cochrane Library, Issue 4. Chichester: John Wiley and Sons, Ltd.
43. Thomson, J., Rankin, H., Ashcroft, G., Yates, C., McQueen, J., & Cummings, S. (1992). The treatment of depression in general practice: A comparison of L-tryptophan, amytriptyline, and a combination of L-tryptophan and amytriptylin with placebo. Psychological Medicine, 12, 741-751.
44. Turner, E. H., Loftis, J. M., & Blackwell, A. D. (2006). Serotonin a la carte: Supplementation with the serotonin precursor 5-hydroxytryptophan. Pharmacology and Therapeutics, 109, 325-338.
45. Van Praag, J., Korf, J., Dols, L., & Scut, T. (1972). A pilot study of the predictive value of the probenecid test in the application of 5-hydroxytryptophan as antidepressant. Psychopharmacology, 25, 14-21.
46. Van Praag, H. M., & de Hahn, S. (1981). Chemoprophylaxis of depressions. An attempt to compare lithium with 5-hydroxytryptophan. Acta Psychiatric Scandinavia, Supplement 290, 191-201.